Cargando…
Gut Microbial β-Glucuronidase Inhibition via Catalytic Cycle Interception
[Image: see text] Microbial β-glucuronidases (GUSs) cause severe gut toxicities that limit the efficacy of cancer drugs and other therapeutics. Selective inhibitors of bacterial GUS have been shown to alleviate these side effects. Using structural and chemical biology, mass spectrometry, and cell-ba...
Autores principales: | Pellock, Samuel J., Creekmore, Benjamin C., Walton, William G., Mehta, Naimee, Biernat, Kristen A., Cesmat, Andrew P., Ariyarathna, Yamuna, Dunn, Zachary D., Li, Bo, Jin, Jian, James, Lindsey I., Redinbo, Matthew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062831/ https://www.ncbi.nlm.nih.gov/pubmed/30062115 http://dx.doi.org/10.1021/acscentsci.8b00239 |
Ejemplares similares
-
Structure, function, and inhibition of drug reactivating human gut microbial β-glucuronidases
por: Biernat, Kristen A., et al.
Publicado: (2019) -
Mouse Gut Microbiome-Encoded β-Glucuronidases Identified Using Metagenome Analysis Guided by Protein Structure
por: Creekmore, Benjamin C., et al.
Publicado: (2019) -
Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy
por: Bhatt, Aadra P., et al.
Publicado: (2020) -
Microbial β-glucuronidases drive human periodontal disease etiology
por: Lietzan, Adam D., et al.
Publicado: (2023) -
Characterizing the metabolic effects of the selective inhibition of gut microbial β-glucuronidases in mice
por: Letertre, Marine P. M., et al.
Publicado: (2022)